Clinical Trial Update: Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bortezomib, dexamethasone, and rituximab in previously untreated Waldenström's macroglobulinemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Rituximab (rituximab)

Snippet

Sponsor: Meletios A. Dimopoulos | Conditions: Waldenstrom's Macroglobulinemia | Phase 2 | Status: COMPLETED